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Abstract
The purpose of this study was to investigate the characteristics of ochratoxin A (OTA) transport by multispecific human organic anion
transporter 4 (hOAT4) using mouse proximal tubule cells stably transfected with hOAT4 (S2 hOAT4). Immunohistochemical analysis
revealed that hOAT4 protein was localized to the apical side of the proximal tubule. S2 hOAT4 expressed hOAT4 protein in the apical side as
well as basolateral side and the cells were cultured on the plastic dish for experiments. S2 hOAT4 exhibited a time- and concentration-
dependent, and a saturable increase in OTA uptake, with an apparent Km value of 22.9F 2.44 AM. The OTA uptakes were inhibited by
several substrates for the OATs. Probenecid, piroxicam, octanoate and citrinin inhibited OTA uptake by hOAT4 in a competitive manner
(Ki = 44.4–336.4 AM), with the following order of potency: probenecid>piroxicam>octanoate>citrinin. The efflux of OTA by S2 hOAT4 was
higher than that by mock. Addition of OTA resulted in slight decrease in viability of S2 hOAT4 compared with mock. These results indicate
that hOAT4 mediates the high-affinity transport of OTA on the apical side of the proximal tubule, whereas the transport characteristics of
OTA are distinct from those by basolateral OATs. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Ochratoxin A (OTA) is a naturally occurring mycotoxin
produced as a secondary metabolite in different species of
Aspergillus and Penicillum [1]. Contamination of foods,
particularly cereals, nuts and coffee beans, with OTA has
been noted in Eastern and Central Europe, North Africa,
North America and Japan [2]. As shown in Fig. 1A, OTA is
a structural analogue of phenylalanine and contains a
chlorinated dihydroisocoumarin moiety [3]. Recently, OTA
has received considerable attention because of its deleteri-
ous effects on human and animal health. OTA accumulates
in several tissues in the body, with the kidney being its main
target where it exerts toxic and carcinogenic effects [4].
Three forms of human renal disease appear to be also caused,
at least in part, by enhanced exposure to OTA: Balkan
endemic nephropathy, chronic interstitial nephritis and kar-
yomegalic interstitial nephritis [5]. However, the pathophy-
siological role of OTA in human renal disease has not yet
been completely determined.
In the kidney, OTA mainly impairs proximal tubular
functions and causes glucosuria, enzymuria and a decrease
in para-aminohippuric acid (PAH) transport [6–8]. An in
vivo study revealed that probenecid, a typical inhibitor of
organic anion transporter (OAT), inhibited the renal clear-
ance of OTA [9]. From these results, it is thought that the
excretion of OTA into the urine is mainly by tubular
secretion, presumably via the OAT system, and this may
play an important role in OTA accumulation and develop-
ment of nephrotoxicity. On the other hand, the mechanism
for the reabsorption of OTA on the apical side of the
proximal tubule has been elucidated in membrane vesicles,
cultured cells and isolated proximal tubules [9–12]. Using
the rat nephron segments, it was shown that pH-independent
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reabsorption of OTA in the proximal straight tubule is
mediated by OAT-K1, whereas pH-dependent reabsorption
in the proximal convoluted tubule is mediated by H + -
dipeptide co-transporter [8,11]. However, the molecular
mechanism for the apical OTA transport remains unknown.
The secretion or reabsoption of various anionic substan-
ces, drugs and xenobiotics is an important physiological
function of the renal proximal tubule [13]. Recently, cDNAs
encoding transporters mediating organic anion transport
have been successively cloned, including OAT1 [14,15],
OAT2 [16], OAT3 [17,18], OAT4 [19], OAT-K1 [20], OAT-
K2 [21], organic anion-transporting polypeptide (oatp1)
[22], oatp2 [23], oatp3 [24], multiple resistance-associated
protein 2 (MRP2) [25] and human-type I sodium-dependent
inorganic phosphate transporter (NPT1) [26].
We have recently characterized OTA transport by human
OAT1 (hOAT1) and human OAT3 (hOAT3) using proximal
tubule cells stably expressing hOAT1 and hOAT3 (S2
hOAT1 and S2 hOAT3) [27]. In the current study, we
undertook to elucidate the role of human OAT4 (hOAT4)
in OTA transport on the apical side of the proximal tubule
using mouse proximal tubule cells stably transfected with
hOAT4.
2. Materials and methods
2.1. Materials
[3H]OTA (547.6 GBq/mmol) was purchased from Mor-
avek Biochemicals Inc. (Brea, CA, USA). [3H]Estrone
sulfate (ES) (1961 GBq/mmol) and [14C]mannitol (532.4
GBq/mmol) were purchased from Perkin Elmer Life Scien-
ces (Boston, MA, USA). OTA, PAH, citrinin, octanoate,
piroxicam, penicillin G, cimetidine, aspartame and indome-
thacin were obtained from Sigma Chemical Co. (St. Louis,
MO, USA). Fetal bovine serum (FBS), trypsin and geneticin
were from Gibco/BRL (Gaithersburg, MD, USA), recombi-
nant epidermal growth factor (EGF) were from Wakunaga
(Hiroshima, Japan), insulin was from Shimizu (Shizuoka,
Japan), RITC 80-7 culture medium was from Iwaki Co.
(Tokyo, Japan), and TfX-50 was from Promega (Madison,
WI, USA).
2.2. Immunohistochemical analysis of hOAT4 protein in
human kidney
For the generation of antibody against hOAT4, rabbits
were immunized with keyhole limpet hemocyanin-conju-
gated synthesized peptides, GNRQEAVTVESTSL, corre-
sponding to cysteine and the 14 amino acids of the COOH
terminus of hOAT4.
Light-microscopic analysis of the hOAT4 protein was
performed as previously described [28]. Briefly, waxed
sections (2 Am) were cut and stained by the labeled
streptavidin–biotin method. After dewaxing, the sections
were incubated with 3% H2O2 for 15 min and then with
blocking serum for 15 min. The sections were then incu-
bated with a polyclonal antibody against hOAT4 (1:500
dilution) for 2 h. The sections were rinsed with Tris-buffered
saline containing 0.1% Tween 20 (TBST) and incubated
with the biotinylated secondary antibody against rabbit
immunoglobulin (Dako, Glostrup, Denmark) for 1 h. After
rinsing with TBST, the sections were incubated for 30 min
with horseradish peroxidase (HRP)-conjugated streptavidin
solution. HRP labeling was detected using a peroxidase
substrate solution with diaminobenzidine (0.8 mM; Dojindo
Laboratories, Kumamoto, Japan). The sections were coun-
terstained with hematoxylin before examination under a
light microscope. For preabsorption experiment, the hOAT4
peptide (200 Ag/ml) was added to the hOAT4-specific
antibody solution and incubated overnight at 4 jC. Using
this preabsorbed antibody, the immunohistochemistry was
performed as described above.
2.3. Cell culture and establishment of cells stably expressing
hOAT4
As described previously [29], the second portion of the
proximal tubule (S2), derived from transgenic mice harbor-
ing the temperature-sensitive simian virus 40 large T-antigen
Fig. 1. Chemical structure of ochratoxin A (A), aspartame (B) and piroxicam
(C).
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gene was microdissected and S2 cells were established. The
full-length cDNA of hOAT4 [19] was subcloned into
pcDNA3.1 (Invitrogen, Carlsbad, CA, USA), a mammalian
expression vector. S2 cells stably expressing hOAT4 (S2
hOAT4) were obtained by transfecting S2 cells with
pcDNA3.1-hOAT4 coupled with pSV2neo, a neomycin
Fig. 2. Immunohistochemical staining illustrating hOAT4 protein in human kidney and cells stained with polyclonal antibody against hOAT4. (A) human
kidney cortex ( 100), (B) human kidney cortex( 400), (C) human kidney medulla ( 100), (D) human kidney cortex ( 400), (E) S2 hOAT4 ( 100) and
(F) mock ( 100). Immunoreactivity was completely abolished by pretreatment of antibody with hOAT4 oligopeptide (D). a: arteriole, C: cortical collecting
duct, D: distal tubule, O: outer medullary collecting duct and P: proximal tubule.
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resistance gene, using a liposome [30]. S2 cells transfected
with pcDNA3.1 lacking an insert and pSV2neo were des-
ignated as S2 pcDNA3.1 and used as the control (mock). S2
hOAT4 and mock were grown in a humidified incubator at
33 jC and 5% CO2, using RITC 80-7 medium that con-
tained 5% FBS, 10 Ag/ml transferrin, 0.08 U/ml insulin, 10
ng/ml recombinant EGF and 400 Ag/ml geneticin [30]. The
cells were subcultured in a medium containing 0.05%
trypsin–EDTA solution (containing in mM: 137 NaCl, 5.4
KCl, 5.5 glucose, 4 NaHCO3, 0.5 EDTA and 5 HEPES; pH
Fig. 2 (continued ).
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7.2) and used for 25–30 passages. Clonal cells were isolated
using a cloning cylinder, and screened by determining the
optimal substrate for hOAT4, [3H]ES [19]. S2 hOAT4
exhibited a dose- and time-dependent increase in ES uptake
activities. The S2 monolayer was determined to be leaky
based on the results of a study wherein we estimated
paracellular secretion from cells cultured on a permeable
support, using D-[14C]mannitol as an indicator. Light-micro-
scopic analysis of the hOAT4 protein in S2 hOAT4 was
performed as previously described [30]. The cells were
cultured on Transwell chambers (Coster, Cambridge, MA,
USA). After the cells were washed three times with 50 mM
NH4Cl in phosphate-buffered saline (PBS) (containing in
mM: 136 NaCl, 2.7 KCl, 8.2 NaHPO412H2O and 15
KHPO4, pH 7.4), they were fixed with paraformaldehyde
lysine periodate (PLP) solution (containing 0.01 M NaIO4,
0.075 M lysine, 0.0375 M phosphate buffer with 2%
paraformaldehyde; pH 6.2) for 2 h at 4 jC. The fixed cells
were stained with the antibody against hOAT4 and HRP as
described above. In addition, vertical sections of S2 hOAT4
stained with polyclonal antibody against hOAT4, showed
that the subcellular localization of hOAT4 protein was
mainly on the cell membrane (Fig. 2E), whereas no staining
was observed in mock (Fig. 2F). Both the basolateral and
apical portions of the membrane showed positive staining.
Therefore, the cells were cultured on a solid support for use
in the following experiments.
2.4. Uptake experiment
Uptake experiments were performed as previously
described [30]. The S2 cells were seeded in 24-well tissue
culture plates at a cell density of 1105 cells/well. After 2
days of culture, the cells were washed three times with
Dulbecco’s modified PBS (D-PBS) solution (containing in
mM: 137 NaCl, 3 KCl, 8 NaHPO4, 1 KH2PO4, 1 CaCl2 and
0.5 MgCl2; pH 7.4) containing 5 mM D-glucose, and then
preincubated with the same solution for 10 min in a water
bath at 37 jC. The cells were then incubated in D-PBS
containing 5 mM D-glucose with [3H]OTA at 100 nM for
time course experiments, and 1 AM for inhibition experi-
ments at 37 jC. The uptake was stopped by the addition of
ice-cold D-PBS, and the cells were washed three times with
the same solution. The cells in each well were lysed with 0.5
ml of 0.1 N sodium hydroxide and 2.5 ml of aquasol-2, and
radioactivity was determined using a h-scintillation counter
(Aloka, LSC-3100).
2.5. Inhibition study
To evaluate the inhibitory effects of several substrates for
an OAT on hOAT4-mediated OTA uptake, S2 hOAT4 was
incubated for 1 min at 37 jC in D-PBS containing 1 AM
[3H]OTA in the absence or presence of various inhibitors
(0.2 mM) including PAH, probenecid, penicillin G, aspar-
Fig. 2 (continued ).
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tame, octaonate, cimetidine, citrinin, indomethacin and
piroxicam. PAH, probenecid, penicillin G and cimetidine
were dissolved in D-PBS. Indomethacin was initially dis-
solved in ethanol and then diluted with D-PBS. Aspartame,
octanoate, citrinin and piroxicam were dissolved in dime-
thylsulfoxide and then diluted with the incubation medium.
The final concentrations of ethanol and dimethylsulfoxide
were adjusted to less than 0.1%, which did not affect the
hOAT4-mediated OTA uptake in our system.
2.6. Kinetic analysis
After preincubation as described above, S2 hOAT4 was
incubated for 1 min at 37 jC in D-PBS containing different
concentrations of [3H]OTA in the absence or presence of
various inhibitors. The concentrations of the inhibitors used
are listed in the Table 1. On the basis of [3H]OTA uptake
under each condition, double reciprocal plot analyses were
performed as previously described [31]. When the inhibition
was found to be competitive, Ki values were calculated
based on the following equation:
Ki ¼ concentration of inhibitor=½ðKm OTA with inhibitor
=Km OTA without inhibitorÞ  1
2.7. Efflux study
Efflux study was performed as previously described
[30]. S2 hOAT4 and mock were seeded in 24-well tissue
Table 1
The Ki values of the inhibitory effects of various substrates on OTA uptake
by hOAT4
Drug Ki
value
(AM)
Inhibitor
(AM)
Total plasma
concentration
(AM)
Unbound
fraction
(%)
Unbound
plasma
concentration
(AM)
Probenecid 44.4 500 170 [40] 11.0 [41] 18.7
Piroxicam 107.8 400 24.0 [42] 0.02 [42] 0.0048
Octanoate 235.5 1000
Citrinin 366.4 1000
S2 hOAT4 was incubated with solution containing various concentrations of
[3H]OTA in the absence or presence of various substrates at 37 jC. The Ki
values were estimated from a Lineweaver–Burk plot.
Fig. 3. Time course of OTA uptake by hOAT4. S2 hOAT4 and mock were
incubated in solution containing 100 nM [3H]OTA at 37 jC for 30 s to
5 min. Each value represents the meanF S.E. of four determinations.
Fig. 4. Specificity of OTA uptake by hOAT4. S2 hOAT4 and mock were
incubated in solution containing 100 nM [3H]OTA and 100 nM
[14C]mannitol at 37 jC for 5 min. (A) OTA, (B) mannitol. Each value
represents the meanF S.E. of four determinations. *P < 0.05 and * *P <
0.001 vs. mock.
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culture plates at a cell density of 1105 cells/well. After
the cells were cultured for 2 days, they were washed three
times with D-PBS and then preincubated in the same
solution for 10 min in a water bath at 37 jC. Thereafter,
the monolayers were incubated with 300 nM [3H]OTA for
30 min at 37 jC, washed immediately once with 1500 Al
D-PBS, and incubated at 37 jC with 500 Al of D-PBS.
Since the time course of OTA efflux was prompt and three
times washing of cells takes time, the significant amount of
OTA was effluxed during washing of cells with 500 Al D-
PBS. Thus, in order to minimize the OTA efflux during
washing, the cells were washed once with 1500 Al D-PBS.
After the incubation for the indicated periods of time, 50 Al
of the supernatant was collected. Then, the medium was
aspirated immediately and the cell monolayers were washed
three times with the medium and solubilized in 0.5 ml of 0.1
N sodium hydroxide. The radioactivities within the super-
natant and cell lysates were measured by counting the
radioactivity. The rate of efflux at each time point was
presented using the following formula: (effluxed [3H]OTA
by S2 hOAT4 effluxed [3H]OTA by mock)/([3H] OTA by
S2 hOAT4 at time 0 [3H]OTA accumulated by mock at
time 0).
2.8. Cell viability assay
Cell viability was assessed using the MTT assay
[30,32,34]. As described above, after S2 hOAT4 and mock
were seeded at a cell density of 2 105 cells/well in 24-
well plates and cultured for 2 days, cells were cultured in a
medium containing 5% FBS with or without OTA for 2
days at 33 jC. The number of S2 hOAT4 and mock 2 days
after inoculation was 6 105 and 4 105 cells/well,
respectively. After incubation, 50 Al of 5 mg/ml of MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) was added to the medium (0.5 ml), and the cells
were further incubated for 4 h. After solubilizing the cells
with isopropanol/HCl solution, optical intensity was meas-
ured at 570 nm with 630 nm as the reference (Beckman,
Du640).
2.9. Statistical analysis
Data are expressed as means + S.E. Statistical differences
were determined using Student’s unpaired t-test. Differences
were considered significant at P < 0.05.
Fig. 6. Effects of various inhibitors on hOAT4-mediated OTA uptake. S2
hOAT4 was incubated in solution containing 1 AM [3H]OTA in the absence
or presence of various inhibitors (0.2 mM) at 37 jC for 1 min. Each value
represents the meanF S.E. of four determinations. *P < 0.05, **P < 0.01
and ***P < 0.001 vs. control.
Fig. 5. Concentration dependence of OTA uptake by hOAT4. (A) Con-
centration dependence and (B) Eadie–Hofstee plot of the uptake of
[3H]OTA. S2 hOAT4 and mock were incubated in solution containing 2.5 to
40 AM [3H]OTA at 37 jC for 1 min. The values for the uptake by mock were
subtracted from those by S2 hOAT4. Each value represents meanF S.E. of
four determinations from one typical experiment.
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3. Results
3.1. Immunohistochemical analysis of hOAT4 protein in
human kidney
Light-microscopic analysis of 2-Am waxed sections
demonstrated that there was specific immunostaining for
hOAT4 in the proximal tubules (Fig. 2A–C). As shown in
Fig. 2A and B, in the cortex, there was staining for hOAT4
in the proximal convoluted tubules. In addition, in the outer
medulla, hOAT4 was located in the proximal straight
tubules (Fig. 2C). In contrast, no immunostaining for
hOAT4 was observed in glomeruli, the other nephron seg-
ments and arterioles. By preincubation of the antibody with
hOAT4 peptide, the immunostaining was completely dimin-
ished (Fig. 2D). The specificity of the antibody for hOAT4
was verified by these results.
3.2. OTA uptake by hOAT4
We evaluated the time-dependent uptake of OTA in S2
hOAT4. As shown in Fig. 3, the amount of OTA uptake
Fig. 7. Kinetic analysis of the inhibitory effects of various inhibitors on OTA uptake by hOAT4. S2 hOAT4 was incubated in solution containing various
concentrations of [3H]OTA (2.5–80 AM) in the presence or absence of probenecid (A), piroxicam (B), octanoate (C) and citrinin (D) at 37 jC for 1 min, and
analysis of Lineweaver–Burk plots was performed from one typical experiment.
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by S2 hOAT4 was significantly higher than that by mock.
In order to confirm the specificity of OTA uptake medi-
ated by hOAT4, S2 hOAT4 and mock were incubated in a
solution containing 100 nM [3H] OTA and 100 nM [14C]
mannitol for 5 min. As shown in Fig. 4, both OTA (A)
and mannitol (B) uptake values by S2 hOAT4 were higher
than that by mock (N = 4, *P < 0.05 and **P < 0.001 vs.
mock). However, OTA uptake by hOAT4 was approxi-
mately fourfold of that by mock, whereas mannitol uptake
by hOAT4 was approximately twofold of that by mock.
Thus, it was suggested that hOAT4 mediates the specific
uptake of OTA. The concentration dependence of hOAT4-
mediated OTA uptake was examined. The specific uptake
of OTA in S2 hOAT4 revealed saturable kinetics (Fig.
5A), and the Eadie–Hofstee plot gave a single straight
line (Fig. 5B). The estimated Km value for hOAT4-
mediated OTA uptake was 22.9F 2.44 AM (N = 4). The
results suggest that hOAT4 is responsible for the high-
affinity transport of OTA.
3.3. Inhibitory effects on OTA uptake by hOAT4
We examined the effects of various substrates on OTA
uptake by hOAT4. The substances used were as follows:
PAH, probenecid (an organic anion transport inhibitor),
penicillin G, aspartame (an artificial sweeter), octaonate (a
fatty acid), citrinin (mycotoxin), cimetidine (a H2 receptor
antagonist as well as an organic cation transport inhibitor),
indomethacin and piroxicam (an anti-inflammatory drugs).
These substances except cimetidine are organic anions.
Aspartame is the N-aspartl-phenylalanine methyl ester, thus
a structural analogue of phenylalanine and OTA [33] (Fig.
1A). In addition, as shown in Fig. 1C, piroxicam also
exhibited structural analogy to OTA. We have already
determined the inhibitory effects of these substances on
rat-OAT1-, hOAT1- and hOAT3-mediated OTA uptake
[27,34], and other researchers have also found the inhibitory
effects of some of the substances on OTA transport in
tubules or cells [33,35–39]. As shown in Fig. 6, probenecid,
penicillin G, aspartame, octanoate, citrinin, indomethacin
and piroxicam significantly inhibited hOAT4-mediated OTA
uptake (N = 4, *P < 0.05, **P < 0.01 and ***P < 0.001 vs.
control), whereas PAH and cimetidine did not (N = 4, N.S.).
3.4. Kinetic analysis of inhibitory effects of various drugs on
OTA uptake by hOAT4
To further elucidate the inhibitory effects of hOAT4-
mediated OTA uptake, inhibitory kinetics of probenecid,
piroxicam, octanoate and citrinin was analyzed. Typical
results are shown in Fig. 7. The Lineweaver–Burk plot
analysis of probenecid (A), piroxicam (B), octanoate (C)
and citrinin (D) inhibition on hOAT4-mediated OTA uptake
demonstrated that these compounds inhibited OTA uptake
by hOAT4 in a competitive manner. The Ki value for each
inhibitor tested is shown in the Table 1.
3.5. Efflux of OTA by hOAT4
In order to determine whether hOAT4 mediates the efflux
of OTA, we compared the efflux of OTA by S2 hOAT4 with
that by mock. As shown in Fig. 8, S2 hOAT4 exhibited
significant amount of OTA efflux, in which the amount of
OTA efflux by mock was subtracted.
Fig. 8. Efflux of OTA by hOAT4. After 30 min of incubation in a solution
containing 300 nM [3H]OTA at 37 jC, S2 hOAT4 and mock were incubated
in solution at 37 jC for 30 min. The amount of [3H]OTA within the
supernatant and the cell lysate was determined. The rate of efflux at each
time point was presented as the following formula: (effluxed [3H]OTA by
the S2 hOAT4 effluxed[3H]OTA by mock)/([3H]OTA accumulated by S2
hOAT4 at time 0 [3H]OTA accumulated by mock at time 0). Each value
represents the mean + S.E. of three determinations.
Fig. 9. Effects of OTA on viability of S2 hOAT4. S2 hOAT4 and mock were
cultured in medium containing 5% FBS in the absence or presence of
various concentrations of OTA at 33 jC for 48 h. Each value represents the
meanF S.E. of four determinations.
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3.6. Effects of OTA on viability of S2 hOAT4
To elucidate the cytotoxic effects of OTA on S2 hOAT4,
S2 hOAT4 and mock were cultured for 48 h in the absence
or presence of various concentrations of OTA. As shown in
Fig. 9, OTA slightly inhibited viability in S2 hOAT4
compared with mock, and no significant difference was
observed (N = 4, N.S. vs. mock).
4. Discussion
HOAT4 was isolated from human placenta and also
shown to be localized to the kidney [19]. HOAT4 mediated
the uptake of various substrates including PAH, ES and
dehydroepiandrosterone sulfate; however, its substrate spe-
cificity was relatively narrow compared with that of hOAT1
and hOAT3. In the current study, hOAT4 was shown to be
localized to the apical membrane of the proximal tubule
within the kidney. Based on this, we characterized OTA
transport using S2 hOAT4. In S2 hOAT4, hOAT4 is sorted to
the apical side as well as the basolateral side (Fig. 2E). Thus,
in confluent monolayers of S2 hOAT4 on the plastic dish,
not only the apical side but also the lateral side of hOAT4
protein could be exposed to uptake solution containing
various substrates because tight junction is leaky. In this
regard, we have also isolated Madin–Darby canine kidney
(MDCK) cells stably expressing hOAT4 (MDCK hOAT4),
where the unidirectional transport of OTA from the baso-
lateral side to the apical side of the cells on the permeable
support was recognized and tight junction was well devel-
oped (data not shown). The Km value for hOAT4-mediated
OTA uptake in MDCK hOAT4 cultured on the plastic dish
was similar to that in S2 hOAT4, i.e., 56.2F 4.12 AM
(unpublished observation).
In the current study, hOAT4-mediated OTA uptake was
found to increase in a dose- and time-dependent manner and
was saturable. The crucial parameter for the estimation of
the transport rate of a substrate is the concentration of its
free, unbound form. In this regard, although more than 99%
of OTA is bound to plasma proteins [43,44], only little
albumin is filtered by the glomerulus while free OTA is
filtered. Thus, free OTA concentration in the primary urine
is not necessarily negligible in the uptake of OTA into the
proximal tubule. In addition, hOAT4-mediated OTA uptake
was inhibited by various substrates for OATs. Furthermore,
hOAT4 mediated the efflux of OTA. Thus, it was suggested
that hOAT4 mediates the reabsorption and the efflux of
OTA on the apical side of the proximal tubule.
The intracellular content of OTA in S2 hOAT4 preincu-
bated in a solution containing 300 nM [3H]OTA for 30 min
was 2.11 pmol/mg protein. The intracellular volume of
cultured fibroblasts was reported to be 3.0 Al/106 cells using
[14C]urea [45]. Assuming that the intracellular volume of S2
hOAT4 is similar to that of fibroblasts, the intracellular
concentration of OTA in S2 hOAT4 preincubated for 30 min
is estimated as 1.17 AM. According to the results of dose-
dependent experiments (Fig. 5A), OTA uptake by S2 hOAT4
incubated in a solution containing 1.17 AM [3H]OTA for 2
min was 5.57 pmol/mg protein. On the other hand, during
the 2-min efflux after 30-min incubation, OTA efflux by S2
hOAT4 was 0.99 pmol/mg protein. Based on these, OTA
efflux activity by S2 hOAT4 appears to be much lower than
OTA uptake activity.
To our knowledge, there are some reports concerning the
involvement of apical OATs in the transport of OTA. oatp-1
was shown to mediate the reabsorption of OTA (Km = 18.9
AM) [46]. In addition, as described above, OAT-K1 was
thought to mediate the pH-independent reabsorption of OTA
in the proximal straight tubule [8]. Furthermore, MRP2
mediated the efflux of OTA [25]. The relative contribution
of these OATs including oatp-1, OAT-K1, MRP2 and
hOAT4 to the reabsorption and the efflux of OTA on the
apical side of the proximal tubule should be elucidated in
future studies. In addition to these apical OATs, the role of
OAT-K2 [21], oatp-1 [22] and NPT1 [26] in the transport of
OTA should be further clarified.
The hOAT4-mediated OTA uptake was significantly
inhibited by the presence of probenecid, penicillin G,
aspartame, octaonate, citrinin, indomethacin and piroxicam.
These results are consistent with those of previous reports
that various substrates for OATs including PAH, probenecid,
piroxicam and octanoate inhibited peritubular OTA uptake
or OTA secretion in rabbit isolated proximal tubules [35–
39]. In addition, the results of the inhibition experiments
were in contrast to the previous results that these inhibitors,
except aspartame, exhibited significant inhibitory effects on
OTA uptake by basolateral OATs, hOAT1 and hOAT3 [27].
The rank order of Ki values of various inhibitors of hOAT4-
mediated OTA uptake was the same as that for hOAT3- but
not hOAT1-mediated OTA uptake [27]. The Ki values of
probenecid, piroxicam, octanoate and citrinin for hOAT4-
mediated OTA uptake were much higher than those for
hOAT1- and hOAT3-mediated OTA uptake except that of
citrinin for hOAT1-mediated OTA uptake (more than three-
fold) [27,47]. Thus, it was suggested that there exist some
differences in the affinity and the effects of various sub-
strates on OTA uptake between apical OAT (hOAT4) and
basolateral OATs (hOAT1 and hOAT3). As far as we know,
there is only one report describing the effects of these
substrates on the apical OTA transport, i.e., aspartame
exhibited no significant inhibitory effects on apical OTA
uptake in MDCK cells [37]. The discrepancy between the
result of this study and our result may be due to the OTA
uptake in MDCK cells mediated not only by OAT but also
by proton-dependent peptide transporter.
In humans, the steady-state maximum plasma concen-
tration of probenecid was reported to be 170 AM [40] and its
unbound fraction was 11.0% [41]. Thus, the steady-state
maximum concentration of unbound probenecid in the
plasma was estimated to be 18.7 AM. Since the therapeuti-
cally relevant concentration of a drug in the plasma are
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thought to be within fivefold of the steady-state maximum
concentration of a drug in the plasma [48], the therapeuti-
cally relevant concentration of unbound probenecid in the
plasma is though to be within 93.5 AM. In addition, since an
unbound drug is filtered through glomerulus, the concen-
tration of unbound probenecid within the tubular fluid in the
proximal tubule may be within 93.5 AM. Thus, the Ki value
of probenecid for hOAT4-mediated OTA uptake (4.40 AM)
was much lower than the concentration of unbound probe-
necid within the tubular fluid in the proximal tubule (more
than threefold) [47]. Based on these, it was predicted that
probenecid within the tubular fluid could inhibit OTA
uptake in the apical side of the proximal tubule.
Piroxicam exhibits inhibitory effects on hOAT4-medi-
ated OTA reabsorption on the apical side of the proximal
tubule. However, piroxicam appears to have no clinical
significance. The steady-state plasma concentration of pir-
oxicam was reported to be 24.0 AM and its unbound fraction
was 0.02% [42]. The steady-state maximum concentration
of unbound piroxicam in the plasma is estimated to be
approximately 0.0048 AM. This concentration of piroxicam
is much lower than the Ki value for hOAT4-mediated OTA
uptake, 4.88 AM.
Since the addition of OTA to S2 hOAT4 culture resulted
in no significant effects on viability compared with mock, it
was suggested that hOAT4-mediated OTA uptake may not
significantly contribute to OTA-induced nephrotoxicity in
vivo. The results were in contrast to those in which addition
of OTA resulted in a significant decrease in the viability of
S2 cells stably expressing hOAT1 and hOAT3 (unpublished
observation). Previous studies have demonstrated that pir-
oxicam was shown to inhibit OTA-induced nephrotoxicity
[49]. In addition, piroxicam inhibited OTA uptake mediated
by hOAT1 and hOAT3 [27], and hOAT4. However, hOAT4
did not mediate OTA-induced nephrotoxicity. These results
suggest that piroxicam prevented OTA-induced nephrotox-
icity by inhibiting hOAT1 and hOAT3. On the other hand,
aspartame was also shown to inhibit OTA-induced neph-
rotoxicity [33,50]. In addition, aspartame inhibited OTA
uptake mediated by hOAT4, but not hOAT1 and hOAT3
[27]. Since hOAT4 did not mediate OTA-induced nephro-
toxicity, it was suggested that aspartame inhibited OTA
uptake by inhibiting some transporters other than hOAT1,
hOAT3 and hOAT4. However, there is another possibility
for the involvement of hOAT4 in the OTA-induced neph-
rotoxicity. Since the Km value of hOAT4 (22. 9 AM) is much
higher than those of hOAT1 (0.42 AM) and hOAT3 (0.75
AM) (more than threefold) [27,47], OTA taken up via
basolateral OATs does not move readily across the apical
membrane. This may lead to the buildup of a high concen-
tration of OTA, resulting in the selective damage of the
proximal tubular cells.
Citrinin is also a nephrotoxic mycotoxin, whose structure
is related to OTA. Citrinin has been shown to cause renal
dysfunction, such as glucosuria and proteinuria [51]. Since
citrinin inhibited hOAT4-mediated OTA uptake in a com-
petitive manner, it is possible that citrinin is taken up by
hOAT4 and accumulated OTA induces OTA-induced neph-
rotoxicity.
In conclusion, these results suggest that hOAT4 mediates
not only reabsorption but also the efflux of OTA in the
apical side of the proximal tubule. In addition, since hOAT4
was originally isolated from human placenta [19], it is
possible that hOAT4 in the human placenta plays some role
in the elimination of toxic substances including OTA from
the fetus.
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